Purpose of review HIV infection is an established risk factor for osteoporosis and bone fracture. Combination antiretroviral therapy (cART) increases bone resorption leading to an additional 2-6% bone mineral density (BMD) loss within the first 1-2 years of therapy. Although tenofovir disoproxil fumarate is often blamed for antiretroviral drug-associated bone loss, evidence abounds to suggest that other agents, including the protease inhibitors (PIs), have adverse bone effects. In the current review, we examine bone loss associated with protease inhibitor use, describing the relative magnitude of bone loss reported for individual protease inhibitors. We also review the potential mechanisms associated with protease inhibitor-induced bone loss.
INTRODUCTION
Combination antiretroviral therapy (cART) is now recommended for all HIV-infected patients regardless of CD4 T cell counts [1 && ,2,3] , and those treated with cART can expect to attain a near-normal life expectancy [4] . However, many will experience agerelated comorbidities including musculoskeletal abnormalities, cardiovascular diseases, renal impairment, and certain non-AIDS associated malignancies with greater frequency and at younger ages than their HIV-uninfected counterparts [5,6 & ,7 & ]. Indeed, HIV infection is now an established risk factor for osteopenia and osteoporosis [8] as defined by the World Health Organization criteria [femoral neck or lumbar spine T-score as measured by dual energy X-ray absorptiometry (DXA) between À1.0 and À2.5 (osteopenia) and less than or equal to À2.5 (osteoporosis)] [9] . cART further aggravates rather than alleviates HIV-associated bone loss by inducing an additional 2-6% loss in bone mineral density (BMD) within the first 2 years of therapy, a rate of bone loss comparable with that seen in postmenopausal osteoporosis, the archetype of fragility bone disease [7 among HIV-infected individuals compared with HIV-uninfected controls was 3.7 [95% confidence interval (CI) 2.3-5.9]; cART use conferred an additional 2.5-fold increased odds of low BMD among HIV-infected patients [16] .
Despite the relatively young age of the HIV/ AIDS population, the high prevalence of fragility bone disease in this group is accompanied by an increasing rate of bone fractures [17] . In the landmark study of Triant et al. [17] involving 8525 HIVinfected patients and 2,208,792 HIV-negative controls, an increase in fracture prevalence of up to fourfold was observed in both sexes over a wide age range. Importantly, although fracture rates in HIV-negative men historically have been low until advanced age, fracture rates in HIV-infected men have risen dramatically even at young ages. For example, age-adjusted fracture rates were two to four-fold higher in the HIV Outpatient Study cohort of 5826 HIV-infected patients compared with HIVuninfected adults in the US general population [18] . In the Veterans Aging Cohort Study Virtual Cohort (VASC-VC) comprising 40,115 HIV-infected patients, fracture rates were 24-32% higher compared with HIV-negative controls, and in the Women's Interagency HIV Study (WIHS) cohort, HIV-infected patients were found to have a greater incidence of fragility fractures than HIV-uninfected patients [19,20 & ] . In addition, a recent Spanish study with 2489 HIV-infected and 1,115,667 HIV-uninfected participants revealed a five-fold higher hip fracture rate among participants with HIV infection [21] , and a large Danish case-control study using nationwide health registry data found a nine-fold higher risk of fracture at the hip in HIV-infected patients compared with HIV-uninfected patients [22 && ]. Of note, data from two prospective cohorts of HIV-infected patients with a median age of 43 years in the USA demonstrated that osteoporosis is associated with a four times greater risk of fracture compared with normal BMD, thus linking osteoporosis with the rising fracture rates observed in the HIV/AIDS population [23 & ], which is in contrast to the general population in which BMD is not a predictor of fracture in younger patients [24] . Taken together, these data suggest that an understanding of the factors underlying HIV/cARTinduced bone loss is needed to guide effective preventive and therapeutic strategies to stem the looming epidemic of bone fracture in the aging HIV/AIDS population. In the current review, we examine the role of the protease inhibitors in HIV/cART-induced bone loss, describing the magnitude of bone loss reported for individual protease inhibitors relative to other protease inhibitors and non-protease inhibitor-based cART. We also review the potential mechanisms associated with protease inhibitorinduced bone loss. Differences in mean % change of both trunk and total body BMD mean % change were statistically significant for men, and were not statistically significant for women. 
THE BONE EFFECTS OF THE HIV PROTEASE INHIBITORS
percentage BMD change in patients receiving EFV vs. LPV/r. However, these studies were limited by their reliance on BMD measurements from whole body DXA rather than measurements obtained at specific body sites. In studies in which BMD loss at specific body sites was compared, significant differences were seen between protease inhibitors and other anchor drugs. In the ACTG substudy A5224 s, there was greater mean percentage BMD loss in the spine among patients receiving ATV/r vs. those receiving EFV, although no statistically significant difference was seen in BMD loss in the hip [26] . Duvivier et al.
[40] also reported a greater loss of BMD in the spine, but not the hip, in patients on a ritonavir-boosted protease inhibitor (PI/r) vs. those on a nonnucleoside reverse transcriptase inhibitor (NNRTI) in the Hippocampe-ANRS 121 study. Finally, Rockstroh et al. found that patients receiving ritonavir-boosted darunavir (DRV/r) with NRTI backbone tenofoviremtricitabine (TDF-FTC) had significantly greater loss of spine, but not hip, BMD than those receiving elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/c/FTC/TDF) [37] . The mechanisms accounting for this difference in body site measurements are unclear, but may be attributable in part to the weaker correlation between site-specific DXA and whole body DXA, particularly at the hip [44] . In addition, it has been speculated that this effect may be because of the faster turnover of trabecular vertebral bone compared with the relatively slow turnover of cortical bone in the hip [26] .
To date, only two randomized clinical trials have compared the BMD loss associated with two different protease inhibitors. In the ACTG substudy 5260 s, no difference was observed in the mean percentage BMD loss in both the spine and hip in patients receiving ATV/r vs. DRV/r; however, patients in both protease inhibitor arms had a greater percentage BMD loss than patients in the integrase strand transfer inhibitor (INSTI) raltegravir (RAL) arm in both the spine and hip [38 && ]. Interestingly, although there was no difference in total body mean percentage BMD loss in the DRV/r and RAL arms, patients in the ATV/r arm experienced more total body BMD loss than those in either of the other two arms [38 && ]. Investigators in the CASTLE substudy reported a greater loss of trunk mean percentage BMD in patients on LPV/r compared with those on ATV/r. Although no statistically significant difference was seen overall in total body mean percentage change between groups, when stratified by sex, greater total body mean percentage BMD loss was seen in men on LPV/r compared with men on ATV/r, whereas no significant difference was seen among women [41 & ]. Although the evidence regarding the effects of protease inhibitors on bone health in treatment experienced patients is less robust, the SPIRAL-LIP study found a 0.01 g/cm 2 increase in the femoral neck BMD of virologically suppressed patients switched from a PI/r-based regimen to a RAL-based regimen, with no statistically significant difference in the total body or total hip BMD [43] .
Although the above results argue that bone loss especially soon after cART initiation is attributable to protease inhibitors, results from other clinical trials suggest that maintaining a protease inhibitor while removing the NRTI backbone also results in less loss of BMD both in viremic and virologically suppressed patients (Table 2) ]. Similar results were seen in a nonrandomized study in which cART-experienced, virologically suppressed patients on a PI/r-based regimen containing TDF were switched from TDF to RAL [50] .
These data suggest that a proportion of the bone loss observed with protease inhibitor use may be attributed to concomitant TDF use. Indeed, RTV has been shown to increase plasma tenofovir (TFV) concentrations by 32-50% [51,52 & ,53], via inhibition of active TFV secretion by the proximal convoluted tubule [54, 55] . Similarly, cobicistat (COBI), a CYP 3A4 inhibitor that acts similarly to RTV to boost protease inhibitor and EVG levels, has been shown to increase plasma TFV concentrations by 24-30%, possibly via the inhibition of gastrointestinal efflux transporter P-glycoprotein (P-gp), resulting in greater TDF absorption [55, 56] . However, as seen in the study by Rockstroh et al., protease inhibitors have an effect on bone loss beyond what can be explained by increased TFV levels by COBI [37] .
Although these studies provide significant evidence that protease inhibitors contribute to bone loss, the choice of a cART regimen is complex, involving many biologic and psychosocial factors. The benefits of cART far outweigh any risks of future bone disease, and protease inhibitors remain part of recommended first-line and salvage regimens [57, 58 && ]. For treatment-naïve patients with known osteoporosis, we concur with the recommendation that the clinician and patient weigh the risks and benefits of initiating a protease inhibitor-based regimen and continue to monitor the patient's bone health [58 && ]. The data are less clear on whether patients with osteoporosis who are virologically suppressed for more than 12-24 months on a protease inhibitor-based regimen would benefit from switching to an alternative regimen.
PROPOSED MECHANISMS OF PROTEASE INHIBITOR-ASSOCIATED BONE LOSS
Despite the abundance of evidence from clinical studies for protease inhibitor-associated bone loss, the underlying mechanism remains unclear. The maintenance of skeletal health and bone homeostasis are complex processes mediated by a balance between osteoblastic bone formation and osteoclastic bone resorption [8, 59] . Osteoblasts are derived from mesenchymal stem cells (MSCs), whereas osteoclasts are cells of monocyte-macrophage origin whose differentiation is regulated by the receptor activator of nuclear factor-kappa B ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG) [60, 61] . Therefore, processes that increase osteoclastic bone resorption relative to osteoblastic bone formation will lead to BMD loss.
DIRECT EFFECTS OF PROTEASE INHIBITOR ON BONE CELLS
Previously, it was thought that the bone effects of the antiretroviral drugs were mediated by direct toxicity of the drugs on bone cells. However, establishing this phenomenon in vivo has been challenging since these drugs are used together in cART. Although certain data suggest that antiretroviral drugs do have effects on osteoclasts and osteoblasts in vitro, and in animal models in vivo, results from these experiments generally have failed to recapitulate the in-vivo bone effects observed in the clinical setting. For example, in in-vitro experiments, the protease inhibitor fosamprenavir (FPV) increases OPG expression and decreases RANKL production, whereas protease inhibitors RTV and saquinavir (SQV) were found to abrogate a physiologic block to RANKL [62, 63] , effects that should result in an increase in BMD rather than the clinically observed loss of BMD. As another example, RTV, long considered a major protagonist of bone loss in humans, was shown in one study to inhibit osteoclast function and suppress osteoclastogenesis in vitro and in vivo by impairing RANKL-induced signaling [60], although RTV concentrations in that study were greater than normal pharmacologic concentrations [64] . Of note, the related protease inhibitor indinavir (IDV) had no effect on osteoclastogenesis [60] . In contrast, other in-vitro data have suggested a potential mechanism for protease inhibitorassociated bone loss. NFV and IDV have been shown to alter osteoblast gene expression leading to a decrease in osteoblastic phenotype including a decrease in bone alkaline phosphatase activity and calcium deposition [65] , whereas an increase in senescence of human MSCs when exposed to ATV and LPV leads to a decrease in differentiation to osteoblasts [59] , which is consistent with clinical observations [26, 40] . Additional studies have demonstrated that RTV, at serum concentrations achieved with standard dosing for protease inhibitor-boosting, increases the differentiation of peripheral blood mononuclear cells (PBMCs) into osteoclasts by upregulating growth factors and suppressing transcripts of antagonists in vitro [64, 66, 67] . A greater effect was observed in bone turnover markers (BTMs) and osteoclast differentiation from PBMCs in sera obtained from women on RTVcontaining regimens compared with sera from HIV-infected women on other cART regimens as well as from HIV-uninfected women [66] . Taken together, these results demonstrate that protease inhibitors have the potential to reduce the RANKL/OPG ratio, inhibit osteoblastic activity, and enhance osteoclast formation. The clinical significance of these effects remains unclear, and further research is needed.
HIV DISEASE REVERSAL AND IMMUNE RECONSTITUTION
Because cART-induced bone loss is universal across all antiretroviral drug classes, it has been speculated that this effect may be because of drug-induced HIV disease reversal and T-cell restoration. Recently, our group examined bone turnover in treatment-naïve HIV-infected patients initiating cART. We observed a surge in bone resorption, starting as early as 2 weeks after cART initiation and lasting through 24 weeks [68 && ]. Because T-cell recovery with cART reaches a significant magnitude by 12 weeks [69] , the time point at which we observed a peak in bone resorption, we speculated that there was a link between immune reconstitution and cARTinduced bone loss [68 && ] . Using an animal model of immune reconstitution created by adoptive transfer of T-cells into T-cell knock-out mice, we demonstrated that immune reconstitution did indeed result in a profound loss in BMD via activation of T-cells and/or other immune cells leading to RANKL and/or tumor necrosis factoralpha (TNF-a) production [70 & ].
ALTERED VITAMIN D METABOLISM BY PROTEASE INHIBITORS
Vitamin D is important for bone metabolism and for maintaining serum calcium levels. Vitamin D insufficiency and deficiency result in some cases in secondary hyperparathyroidism, which in turn stimulates osteoclastogenesis via production of RANKL [71] . Vitamin D deficiency may further lead to osteomalacia (poorly mineralized bone matrix). [76] . Most observational studies have evaluated the association between protease inhibitors and 25-(OH)D levels rather than 1,25-(OH) 2 D levels, and suggest an increase in 25-(OH)D levels with initiation of protease inhibitor therapy, which may be because of inhibition of the conversion of 25-(OH)D [77] [78] [79] . In a small clinical trial of vitamin D-deficient HIV-infected postmenopausal women on cART, supplementation with high-dose cholecalciferol was shown to increase both 25-(OH)D and 1,25-(OH) 2 D levels with concurrent decrease in parathyroid hormone (PTH) levels regardless of protease inhibitor therapy, suggesting that protease inhibitor-induced 25-and 1a-hydroxylase suppression can be overcome, although the kinetics have not been described [80] . Further study of the clinical effects of protease inhibitors on vitamin D metabolism is warranted.
CONCLUSION
The HIV protease inhibitors contribute to bone loss in the setting of HIV infection, which appears to be a class effect that is observed with all protease inhibitors that have been studied. HIV disease reversal and the associated immune reconstitution following cART initiation may play a central role in cARTmediated bone loss. Other potential mechanisms specific to protease inhibitors include the direct
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effect of protease inhibitors on the RANKL/OPG axis and on osteoblasts and osteoclasts, as well as the inhibitory effect of protease inhibitors on vitamin D metabolism. The protease inhibitors remain an important component of cART, and future research is warranted to investigate both the pathophysiology of protease inhibitor-induced bone loss and prevention strategies to impact the long-term health of an aging HIV-infected population. 
